A risk-benefit assessment of losartan potassium in the treatment of hypertension

Drug Safety

Volumn 16, Issue 1, 1997, Pages 56-65

  Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN POTASSIUM; THIAZIDE DIURETIC AGENT; URIC ACID;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ASTHENIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; FATIGUE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSOMNIA; KIDNEY DISEASE; LIVER DISEASE; LIVER METABOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; VERTIGO;

EID: 0031019972     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716010-00004     Document Type: Review

References (33)

1. Johnston CI, Burrell LM. Evolution of blockade of the renin angiotensin system. J Hum Hypertens 1995; 9: 375-80
2. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995 Nov; 346: 1403-7
3. Bauer JH, Reams GP. The angiotensin II type I receptor antagonist. Arch Int Med 1995; 155: 1361-8
4. Burrell LM, Johnston CI. Beyond ACE inhibition - new approaches to the understanding and management of hypertension. Med J Aust 1995; 162: 659-62
5. Abdelrahman A, Burrell LM, Johnston CI. Blockade of the renin angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens 1993; 11: S23-6
6. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51
7. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-21
8. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP 3174 in humans. Clin Pharmacol Ther 1995 Dec; 58: 611-9
9. Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995 Feb; 23 (2): 207-15
10. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996 May; 51 (5): 820-45
11. Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992; 5: 19A-20A
12. Weber MA, Byyny RL, Pratt J, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Int Med 1995 Feb 27; 155: 405-11
13. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32
14. Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-4
15. Dunlay MC, Fitzpatrick V, Chyysant S, et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995 Nov; 9: 861-7
16. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995 Jun; 25: 1345-50
17. Tikkanen I, Omvik P, Jensen H. Comparison of the angiotensin II antagonist, losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13; 1343-51
18. Mallion J-M, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerabilily of once daily losartan potassium compared with captopril in patients with mild to moderate hypertension. J Hypertension 1995; 13 Suppl. 1: S35-41
19. Ruff D, Gazdick LP, Berman R, et al. Comparative effects of combination therapy with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14: 263-70
20. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8(6): 578-83
21. Chan JC, Critchley JA, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995 Sep; 9: 765-71
22. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996 Feb 12; 156: 278-85
23. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7
24. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995 Apr 15; 75: 793-5
25. Lacourciere Y, Brunner H, Irwin R, et al., Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994 Dec; 12: 1387-93
26. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995 Dec 7; 333: 1572
27. Gansevoort RT, De Zeeuw D, Shahinfar S, et al. Effects of angiotensin II receptor antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 Suppl. 2: S37-42
28. Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E-3174, an angiolensin II receptor antagonist in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-40
29. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995 Jan; 25: 37-46
30. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7
31. Kasiske B, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Int Med 1993; 118: 129-38
32. Lewis EJ, Hunsicker LG, Bain RP, et al., Collaborative Study Group. The effect of angiotensin converting enzyme inhibitors in diabetic nephropathy. New Engl J Med 1993; 329: 1456-62
33. Urata H, Boehm K, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-81